After a person quits smoking, an important consideration is how quickly the induction of CYP1A2 dissipates. The primary pharmacokinetic interactions with smoking occur with drugs that are CYP1A2 ...
Figure 1 lists the pharmacokinetic drug interactions with smoking. The most clinically significant interactions appear in the shaded rows and are discussed below.
While the FDA will take into consideration the committee’s vote, the vote is not binding upon the agency. The FDA will make the final decision and has assigned a Prescription Drug User Fee Act (PDUFA) ...
Studies show caffeine response may be partly due to gene variations in the genes CYP1A2 and ADORA2A, which are thought to indicate how slowly or quickly someone can metabolize caffeine.
Dr Grimaldi says if you carry the genetic variation CYP1A2 (AA), for example, you will “almost certainly” metabolise caffeine faster than someone who doesn’t, and therefore feel its effects ...
May be potentiated by systemic CYP3A4 inhibitors, dual CYP3A4/CYP1A2 inhibitors (eg, erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine); consider risks vs benefits prior to concomitant ...